Abstract
RNA interference-mediated gene silencing has the potential to block gene expression. A synthetic double-stranded small interfering RNA (siRNA) based on a sequence motif of 21 nucleotides from human papillomavirus 16 (HPV16) E6E7 bicistronic RNA was found to be a potent siRNA that suppresses expression of both the E6 and E7 oncogenes in HPV16+ CaSki and SiHa cells. When stably expressed as a short hairpin RNA in these cells, however, siRNA silencing of E6 and E7 expression was efficient only at early cell passages, but became inefficient with increased cell passages despite the continued expression of the siRNA at the same level. The loss of the siRNA function was duplicable in stable p53 siRNA cells, but not in stable lamin A/C siRNA cells, suggesting that it is gene selective. The cells resistant to siRNA function retained normal siRNA processing, duplex unwinding and degradation of the unwound sense strand and RNA-induced silencing complex formation, suggesting that loss of the siRNA function occurred at a later step. Surprisingly, the siRNA-resistant cells were found to express notably a cytoplasmic protein of ∼50 kDa that specifically and characteristically interacted with the unwound, antisense strand E7 siRNA. Altogether, our data indicate that a potent siRNA targeting to an essential or regulatory gene might induce a cell to develop siRNA-suppressive function.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aebi U, Cohn J, Buhle L, Gerace L . (1986). Nature 323: 560–564.
Boyer SN, Wazer DE, Band V . (1996). Cancer Res 56: 4620–4624.
Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL, Iggo R . (2003). Nat Genet 34: 263–264.
Brummelkamp TR, Bernards R, Agami R . (2002). Science 296: 550–553.
Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M, Hoppe-Seyler F . (2003). Oncogene 22: 5938–5945.
Doench JG, Petersen CP, Sharp PA . (2003). Genes Dev 17: 438–442.
Dykxhoorn DM, Novina CD, Sharp PA . (2003). Nat Rev Mol Cell Biol 4: 457–467.
Elbashir SM, Lendeckel W, Tuschl T . (2001). Genes Dev 15: 188–200.
Gonzalez SL, Stremlau M, He X, Basile JR, Munger K . (2001). J Virol 75: 7583–7591.
Goodwin EC, Yang E, Lee CJ, Lee HW, DiMaio D, Hwang ES . (2000). Proc Natl Acad Sci USA 97: 10978–10983.
Haley B, Zamore PD . (2004). Nat Struct Mol Biol 11: 599–606.
Hall AH, Alexander KA . (2003). J Virol 77: 6066–6069.
Hammond SM, Bernstein E, Beach D, Hannon GJ . (2000). Nature 404: 293–296.
Howley PM, Lowy DR . (2001). In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B et al. (eds). Field Virology. Lippincott Williams & Wilkins: Philadelphia, pp 2197–2229.
Jiang M, Milner J . (2002). Oncogene 21: 6041–6048.
Kasschau KD, Xie Z, Allen E, Llave C, Chapman EJ, Krizan KA et al. (2003). Dev Cell 4: 205–217.
Kessis TD, Slebos RJ, Nelson WG, Kastan MB, Plunkett BS, Han SM et al. (1993). Proc Natl Acad Sci USA 90: 3988–3992.
Knight SW, Bass BL . (2002). Mol Cell 10: 809–817.
Lecellier CH, Dunoyer P, Arar K, Lehmann-Che J, Eyquem S, Himber C et al. (2005). Science 308: 557–560.
Li H, Li WX, Ding SW . (2002). Science 296: 1319–1321.
Li WX, Li H, Lu R, Li F, Dus M, Atkinson P et al. (2004). Proc Natl Acad Sci USA 101: 1350–1355.
Lu S, Cullen BR . (2004). J Virol 78: 12868–12876.
Mallory AC, Reinhart BJ, Bartel D, Vance VB, Bowman LH . (2002). Proc Natl Acad Sci USA 99: 15228–15233.
Martinez J, Patkaniowska A, Urlaub H, Luhrmann R, Tuschl T . (2002). Cell 110: 563–574.
Mayeda A, Krainer AR . (1999). Methods Mol Biol 118: 309–314.
Nykanen A, Haley B, Zamore PD . (2001). Cell 107: 309–321.
Pfeffer S, Lagos-Quintana M, Tuschl T . (2003). In: Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA et al. (eds). Current Protocols in Molecular Biology. John Wiley & Sons, Inc.: New York, pp 26.4.1–26.4.18.
Pham JW, Pellino JL, Lee YS, Carthew RW, Sontheimer EJ . (2004). Cell 117: 83–94.
Provost P, Dishart D, Doucet J, Frendewey D, Samuelsson B, Radmark O . (2002). EMBO J 21: 5864–5874.
Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A . (2004). Nat Biotechnol 22: 326–330.
Scadden AD, Smith CW . (2001). EMBO Rep 2: 1107–1111.
Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM . (1990). Cell 63: 1129–1136.
Schulze A, Mannhardt B, Zerfass-Thome K, Zwerschke W, Jansen-Durr P . (1998). J Virol 72: 2323–2334.
Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, Zamore PD . (2003). Cell 115: 199–208.
Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR . (2003). Nat Cell Biol 5: 834–839.
Smotkin D, Wettstein FO . (1986). Proc Natl Acad Sci USA 83: 4680–4684.
Soldan SS, Plassmeyer ML, Matukonis MK, Gonzalez-Scarano F . (2005). J Virol 79: 234–244.
Tang S, Zheng ZM . (2002). J Biol Chem 277: 14547–14556.
Tao M, Kruhlak M, Xia S, Androphy E, Zheng ZM . (2003). J Virol 77: 13232–13247.
Tomari Y, Du T, Haley B, Schwarz DS, Bennett R, Cook HA et al. (2004). Cell 116: 831–841.
Vindelov LL . (1977). Virchows Arch B Cell Pathol 24: 227–242.
Vousden KH . (2000). Cell 103: 691–694.
Yaginuma Y, Westphal H . (1991). Cancer Res 51: 6506–6509.
Yang W, Wang Q, Howell KL, Lee JT, Cho DS, Murray JM et al. (2005). J Biol Chem 280: 3946–3953.
Yoshinouchi M, Yamada T, Kizaki M, Fen J, Koseki T, Ikeda Y et al. (2003). Mol Ther 8: 762–768.
Yu JY, DeRuiter SL, Turner DL . (2002). Proc Natl Acad Sci USA 99: 6047–6052.
Zamore PD, Tuschl T, Sharp PA, Bartel DP . (2000). Cell 101: 25–33.
Zeng Y, Yi R, Cullen BR . (2003). Proc Natl Acad Sci USA 100: 9779–9784.
Zhang H, Kolb FA, Brondani V, Billy E, Filipowicz W . (2002). EMBO J 21: 5875–5885.
Zheng ZM, Tao M, Yamanegi K, Bodaghi S, Xiao W . (2004). J Mol Biol 337: 1091–1108.
zur Hausen H . (2002). Nat Rev Cancer 2: 342–350.
Acknowledgements
This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. We thank Reuven Agami for providing pSUPER and pSUPER-p53 vectors, many of our colleagues for their encouragement in the course of these studies, Sohrab Bodaghi in our lab for providing bacterially expressed HPV16 E7 for the Western blot control. We also thank Douglas Lowy, Robert Yarchoan, Peter Palese, Bruce Paterson, Erik Sontheimer, and Natasha Caplen for their critical reading of our manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tang, S., Tao, M., McCoy, J. et al. Short-term induction and long-term suppression of HPV16 oncogene silencing by RNA interference in cervical cancer cells. Oncogene 25, 2094–2104 (2006). https://doi.org/10.1038/sj.onc.1209244
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1209244
Keywords
This article is cited by
-
Cdc6 contributes to abrogating the G1 checkpoint under hypoxic conditions in HPV E7 expressing cells
Scientific Reports (2017)
-
Oncogenes and RNA splicing of human tumor viruses
Emerging Microbes & Infections (2014)
-
Depletion of polycistronic transcripts using short interfering RNAs: cDNA synthesis method affects levels of non-targeted genes determined by quantitative PCR
Virology Journal (2013)
-
Lack of correlation between predicted and actual off-target effects of short-interfering RNAs targeting the human papillomavirus type 16 E7 oncogene
British Journal of Cancer (2013)
-
Inhibition of cervical cancer cell growth in vitro and in vivo with dual shRNAs
Cancer Gene Therapy (2011)
